UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

~~April~~May 2213, 2022

Commission File Number: 001 - 38178

Zealand Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

Sydmarken 11

2860 Søborg (Copenhagen)
Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ¨ Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

~~Furnished~~The audited consolidated financial statements of Zealand Pharma A/S (the “Company”) and its subsidiaries as ~~Exhibit 99.1~~of toand ~~this~~for ~~Report~~the onyear ~~Form~~ended December ~~6-K~~31, is2021 aare ~~company~~included ~~announcement~~in the Zealand Pharma A/S ~~launches~~Annual ~~long-term~~Report ~~incentive~~filed ~~program~~as ~~for Zealand’s~~exhibit ~~Board~~99.1(a) to ofthis ~~Directors~~Form 6-K ~~for~~and ~~2022~~incorporated by reference herein.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Zealand Pharma A/S

By:	/s/ Matthew Dallas

	Name:	Matthew Dallas
	Title:	Chief Financial Officer

Date: ~~April~~May 2213, 2022

EXHIBIT INDEX

Exhibit No.		Description
99.1		Company announcement – No. 14/ 2022
99.1 (a)		Q1 2022 Release

Filing Compare · Zealand Pharma A/S